How many GHRH analogues are there in the research-peptide class?

Four molecules have meaningful research history: Sermorelin (GHRH 1-29 active fragment with no modification), Tesamorelin (44-residue GHRH with N-terminal lipid modification), Modified GRF (1-29) — also called CJC-1295 without DAC (Sermorelin sequence with four amino-acid substitutions for DPP-IV resistance), and CJC-1295 with DAC (Modified GRF + maleimidopropionyl-lysine albumin-binding linker). All four are full agonists at the same pituitary GHRH receptor.

Which GHRH analogue has the longest plasma half-life?

CJC-1295 with DAC has by far the longest plasma half-life — approximately 8 days, achieved through covalent binding to plasma albumin. Tesamorelin and Modified GRF (1-29) both have plasma half-lives of about 30 minutes (achieved through different engineering approaches that block DPP-IV cleavage). Native GHRH (and unmodified Sermorelin) have plasma half-lives measured in minutes.

Which GHRH analogue has the most clinical-trial validation?

Tesamorelin is the most clinically validated GHRH analogue by a wide margin. The phase-3 program in HIV-associated visceral-adipose research and the 2014 NAFLD-extension RCT provide the strongest evidence base in the class. Sermorelin has older clinical-trial work in paediatric GH-deficiency diagnostics but was withdrawn from the US market in 2008. Modified GRF (1-29) and CJC-1295 with DAC have phase-1 and phase-2 work without comparable phase-3 development programs.

Do all GHRH analogues bind the same receptor?

Yes — all four (Sermorelin, Tesamorelin, Modified GRF, CJC-1295 with DAC) are full agonists at the pituitary GHRH receptor (GHRH-R), with comparable binding affinity in the low-nanomolar range. The pharmacological choice between them is not at the receptor — it is at the pharmacokinetic level (half-life, signalling pattern, dosing frequency).

For acute pituitary diagnostic research, which analogue is used?

Sermorelin is the historical standard for acute pituitary-axis diagnostic research because its short half-life produces a single sharp GH pulse from a single injection — which is exactly what a diagnostic test requires. The molecule was approved for paediatric GH-deficiency diagnosis until its US market withdrawal in 2008; modern research applications retain the diagnostic-tool framing.

Are Tesamorelin and CJC-1295 with DAC interchangeable in research protocols?

No. They share receptor pharmacology but differ in signalling pattern (pulsatile vs sustained), dosing frequency (daily vs weekly), and the depth of supporting clinical-trial data. A research protocol that needs preserved physiological GH pulsatility chooses Tesamorelin or Modified GRF (1-29). A protocol that needs sustained multi-day elevation with infrequent dosing chooses CJC-1295 with DAC. Substituting one for the other changes the research question.

Research · GHRH class

Tesamorelin in context: the GHRH-analogue research class

Creator: Wellness Labs Editorial
Published: 2026-06-02
Keywords: GHRH analogues comparison, GHRH analogues, tesamorelin vs sermorelin, modified GRF 1-29, tesamorelin uae, sermorelin research, somatotropic peptides

Wellness Labs Editorial·2 June 2026·8 min read

Medically reviewed by

Wellness Labs Research Team · Research and Editorial

Last reviewed 1 June 2026

Native GHRH is a 44-amino-acid hypothalamic peptide that triggers pituitary growth-hormone release. Its plasma half-life is approximately three to seven minutes — too short for practical research use. Four synthetic analogues have been engineered to solve this half-life problem, each through a different molecular strategy: Sermorelin, Tesamorelin, Modified GRF (1-29), and CJC-1295 with DAC. The class is small enough to map in one place.

Four molecules, four engineering strategies

Native GHRH has the sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg... (continuing to residue 44). The receptor-binding activity is concentrated in the first 29 residues — that’s why all four synthetic analogues use either the 1-29 fragment or a modification of the 1-44 sequence.

The four molecules differ in what they do to extend half-life:

Sermorelin (GHRH 1-29). Simply the first 29 residues of native GHRH, identical sequence, no modification. DPP-IV cleaves it as fast as native GHRH. Half-life ~12 minutes. Used historically as a diagnostic tool for pituitary GH-axis function and in older paediatric GH-deficiency research. Not engineered for chronic administration.
Modified GRF (1-29) — sometimes called “CJC-1295 no DAC”. Sermorelin’s sequence with four amino-acid substitutions (Tyr1 → D-Ala, Ala8 → Gln, Leu27 → Gln27, Arg28 → Ser) that block DPP-IV access. Half-life extends to ~30 minutes. Used in research that wants pulsatile GH release with daily-or-twice-daily dosing.
Tesamorelin (modified GHRH 1-44). The full 44-residue active sequence with an N-terminal trans-3-hexenoyl modification replacing the native tyrosine. The lipid modification blocks DPP-IV access while preserving receptor binding. Half-life ~26-38 minutes. The only GHRH analogue with full phase-3 visceral-adipose clinical-trial data.
CJC-1295 with DAC. Modified GRF (1-29) plus a maleimidopropionyl-lysine linker that covalently binds the free thiol on cysteine-34 of plasma albumin. The albumin-bound complex is too large for renal clearance. Half-life extends to ~8 days. Used in research protocols that want sustained signalling with weekly dosing.

Shared receptor pharmacology

All four molecules are full agonists at the pituitary GHRH receptor (GHRH-R). The receptor is a G-protein-coupled receptor of the secretin family; agonism produces G(s)-coupled cAMP elevation, which drives GH release from somatotroph cells. Binding affinity at the receptor level is comparable across all four — EC50 values in the low-nanomolar range with reasonable consistency between assays.

The pharmacological choice between them is therefore not at the receptor; it is at the pharmacokinetic level — half-life, signalling pattern, dosing frequency. A research protocol that needs preserved pulsatile GH release with administrator control over the timing chooses Sermorelin, Tesamorelin, or Modified GRF (1-29). A protocol that needs sustained multi-day elevation with minimal injection frequency chooses CJC-1295 with DAC.

Depth of clinical-trial data

The four molecules diverge sharply in clinical-trial validation:

Tesamorelin. Two phase-3 randomised controlled trials in HIV-associated lipodystrophy patients [1]. FDA approval in 2010 for that specific indication. Subsequent academic work extends the visceral-adipose research into non-alcoholic fatty liver disease [2]. Multi-year observational follow-up exists.
Sermorelin. Older clinical-trial work in paediatric GH deficiency from the 1980s-1990s established the diagnostic-tool use. The molecule was approved for paediatric GH deficiency diagnosis and was withdrawn from the US market in 2008. Adult-research use is largely off-label and grey-market.
Modified GRF (1-29). Phase-1 pharmacokinetic and tolerability studies; no large-scale phase-3 program. The published research is sufficient to characterise the basic pharmacology but does not establish efficacy for any specific indication.
CJC-1295 with DAC. Phase-1 pharmacology and short-term tolerability studies [3]. Multiple phase-2 trials in different research contexts. No phase-3 program comparable to Tesamorelin’s.

Honest take: Tesamorelin is the most thoroughly clinically-validated GHRH analogue by a wide margin. The other three are research-quality compounds with substantially less depth of clinical-trial data behind them. For a research protocol that needs the most-validated molecule in the class, Tesamorelin is the choice. The others are appropriate for narrower questions where the pharmacology is more relevant than the clinical-trial depth.

UAE research-supply considerations

All four molecules are available in the UAE as lyophilised research-grade powder. Wellness Labs supplies Tesamorelin and CJC-1295 with Ipamorelin (the latter as a stacking pair). For protocols requiring Modified GRF (1-29) or Sermorelin specifically, the UAE research-supply market overlaps substantially with the broader peptide-research catalogue.

Quality verification across the class follows the same framework — HPLC purity ≥98%, mass-spectrometry confirmation of the parent molecule and any modifications (lipid, maleimide), batch-traceable certificate of analysis. The synthesis complexity differs: Sermorelin (29 residues, no modification) is the simplest; Tesamorelin (44 residues + lipid modification) and CJC-1295 with DAC (29 residues + maleimide linker) are the most synthesis-intensive and therefore the most quality-variable across suppliers.

Which GHRH analogue for which research question

Pituitary-axis diagnostic / short-acute-pulse study. Sermorelin. The shortest half-life means the GH response is the clearest single-pulse signal.
Pulsatile GH research with chronic administration. Tesamorelin or Modified GRF (1-29). Both preserve the pulse pattern; Tesamorelin has substantially more clinical-trial validation.
Visceral-adipose tissue research with the most-validated molecule. Tesamorelin. The phase-3 data and downstream NAFLD work are the strongest evidence base in the class.
Sustained multi-day GH elevation with infrequent dosing. CJC-1295 with DAC. The 8-day half-life enables weekly protocols.
Combined GHRH + ghrelin-mimetic signalling. Pair CJC-1295 with DAC + Ipamorelin (the most-common research stack), or Tesamorelin + Ipamorelin if the protocol prefers pulsatile rather than sustained signalling.

Open class-wide research questions

Whether the depot-selectivity Tesamorelin shows for visceral adipose extends across the class at equivalent GHRH-axis signalling. Mechanism work suggests it should; the data is thin for the other three molecules.
Long-term safety comparisons. Only Tesamorelin has multi-year observational follow-up. CJC-1295 with DAC’s albumin-binding mechanism creates a longer-residence-time molecule, which raises unresolved questions about chronic-administration safety that the phase-1/2 trials cannot fully answer.
The optimal combination with ghrelin-mimetics (Ipamorelin, MK-677, etc.) for protocols where both pathways are activated. The stacked-mechanism literature is small and mostly comes from earlier-stage trials.

Frequently asked questions

How many GHRH analogues are there in the research-peptide class?: Four molecules have meaningful research history: Sermorelin (GHRH 1-29 active fragment with no modification), Tesamorelin (44-residue GHRH with N-terminal lipid modification), Modified GRF (1-29) — also called CJC-1295 without DAC (Sermorelin sequence with four amino-acid substitutions for DPP-IV resistance), and CJC-1295 with DAC (Modified GRF + maleimidopropionyl-lysine albumin-binding linker). All four are full agonists at the same pituitary GHRH receptor.
Which GHRH analogue has the longest plasma half-life?: CJC-1295 with DAC has by far the longest plasma half-life — approximately 8 days, achieved through covalent binding to plasma albumin. Tesamorelin and Modified GRF (1-29) both have plasma half-lives of about 30 minutes (achieved through different engineering approaches that block DPP-IV cleavage). Native GHRH (and unmodified Sermorelin) have plasma half-lives measured in minutes.
Which GHRH analogue has the most clinical-trial validation?: Tesamorelin is the most clinically validated GHRH analogue by a wide margin. The phase-3 program in HIV-associated visceral-adipose research and the 2014 NAFLD-extension RCT provide the strongest evidence base in the class. Sermorelin has older clinical-trial work in paediatric GH-deficiency diagnostics but was withdrawn from the US market in 2008. Modified GRF (1-29) and CJC-1295 with DAC have phase-1 and phase-2 work without comparable phase-3 development programs.
Do all GHRH analogues bind the same receptor?: Yes — all four (Sermorelin, Tesamorelin, Modified GRF, CJC-1295 with DAC) are full agonists at the pituitary GHRH receptor (GHRH-R), with comparable binding affinity in the low-nanomolar range. The pharmacological choice between them is not at the receptor — it is at the pharmacokinetic level (half-life, signalling pattern, dosing frequency).
For acute pituitary diagnostic research, which analogue is used?: Sermorelin is the historical standard for acute pituitary-axis diagnostic research because its short half-life produces a single sharp GH pulse from a single injection — which is exactly what a diagnostic test requires. The molecule was approved for paediatric GH-deficiency diagnosis until its US market withdrawal in 2008; modern research applications retain the diagnostic-tool framing.
Are Tesamorelin and CJC-1295 with DAC interchangeable in research protocols?: No. They share receptor pharmacology but differ in signalling pattern (pulsatile vs sustained), dosing frequency (daily vs weekly), and the depth of supporting clinical-trial data. A research protocol that needs preserved physiological GH pulsatility chooses Tesamorelin or Modified GRF (1-29). A protocol that needs sustained multi-day elevation with infrequent dosing chooses CJC-1295 with DAC. Substituting one for the other changes the research question.